Health insurance coverage expanded to Abbott’s Synagis

Health insurance for Synagis (palivizumab) has been further expanded to those infants under less than 12 months after birth, suffering from congenital heart disease due to respiratory syncytial virus (RVS), according to Abbott Korea.

Previously, only those aged at less than 24 months after birth who were confirmed by doctors to have suffered from RVS associated bonchopulmonary dysplasia were...